BA
TEVA icon

Ballew Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Ballew Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-110
Closed -$2K – 399
2018
Q3 		$2K Buy
+110
New +$2.55K ﹤0.01% 413

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Ballew Advisors's TEVA Position: Q4 2018 in Review

Ballew Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 110 shares — an estimated $2K sold.

Ballew Advisors first reported a position in TEVA in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 552 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

  • Ballew Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Ballew Advisors sold 110 Teva Pharmaceuticals shares in Q4 2018, an estimated $2K.
  • Ballew Advisors first reported a position in Teva Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Ballew Advisors's Teva Pharmaceuticals position peaked at $2K in Q3 2018.
  • 552 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.